Patients with a high NTNG1 level in cancer tissues had shorter PFS [median: 11.0 (95% CI 8.9–13.0) vs. 25.0 (95% CI: 17.1–32.9) months, p = 0.010] and PFI [median: 5.0 (95% CI: 2.7–7.3) vs. 20.0 (95% CI: 13.9–26.1) months, p = 0.021], compared with those with a low level (Figures 1C,D). This evidence concerns the gene NTNG1 and cancer.